Published in Eur J Immunol on December 28, 2014
Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity. J Clin Invest (2016) 0.90
The T cell antigen receptor: the Swiss army knife of the immune system. Clin Exp Immunol (2015) 0.82
Structural mechanism underpinning cross-reactivity of a CD8+ T-cell clone that recognises a peptide derived from human telomerase reverse transcriptase. J Biol Chem (2016) 0.79
More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers. Immunology (2015) 0.78
Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. Sci Rep (2016) 0.77
T-cell receptors: tugging on the anchor for a tighter hold on the tumor-associated peptide. Eur J Immunol (2015) 0.75
A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen. J Biol Chem (2016) 0.75
T cell responses to human platelet antigen-1a involve a unique form of indirect allorecognition. JCI Insight (2016) 0.75
Differential scanning fluorimetry based assessments of the thermal and kinetic stability of peptide-MHC complexes. J Immunol Methods (2016) 0.75
In silico and cell-based analyses reveal strong divergence between prediction and observation of T cell recognized tumor antigen T cell epitopes. J Biol Chem (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
MHC ligands and peptide motifs: first listing. Immunogenetics (1995) 7.78
How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol (2006) 7.57
Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature (1996) 6.20
Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol (1991) 4.44
The IMGT/HLA database. Nucleic Acids Res (2012) 3.61
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol (1998) 2.68
Decision making in xia2. Acta Crystallogr D Biol Crystallogr (2013) 2.59
T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat Immunol (2005) 2.52
Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med (2005) 2.22
Human TCR-binding affinity is governed by MHC class restriction. J Immunol (2007) 2.02
The specificity of TCR/pMHC interaction. Curr Opin Immunol (2002) 1.99
Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J (2005) 1.98
Why must T cells be cross-reactive? Nat Rev Immunol (2012) 1.88
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58
Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem (2009) 1.51
Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol (2010) 1.48
TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J Immunol (2011) 1.46
Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol (2012) 1.46
Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol (2012) 1.41
Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J Mol Biol (2007) 1.36
Thermodynamics of T-cell receptor-peptide/MHC interactions: progress and opportunities. J Mol Recognit (2008) 1.34
Structural and biophysical determinants of αβ T-cell antigen recognition. Immunology (2012) 1.30
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29
Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res (2009) 1.26
Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection. PLoS Pathog (2010) 1.18
T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Mol Immunol (2008) 1.18
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem (2012) 1.16
Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood (2012) 1.13
Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol (2009) 1.09
Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules. Immunogenetics (1994) 1.02
Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res (2003) 1.00
Crystal structure of HLA-A*2402 complexed with a telomerase peptide. Eur J Immunol (2006) 0.98
T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting. J Biol Chem (2012) 0.96
T-cell receptor specificity maintained by altered thermodynamics. J Biol Chem (2013) 0.94
T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions. J Biol Chem (2013) 0.93
Improving T cell responses to modified peptides in tumor vaccines. Immunol Res (2013) 0.90
Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability. Mol Immunol (2010) 0.90
Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. Sci Rep (2012) 0.90
TCR/pMHC Optimized Protein crystallization Screen. J Immunol Methods (2012) 0.89
Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine (2007) 0.85
Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. J Biol Chem (2013) 0.81
Unexpected T-cell recognition of an altered peptide ligand is driven by reversed thermodynamics. Eur J Immunol (2012) 0.80
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem (2011) 2.06
Human TCR-binding affinity is governed by MHC class restriction. J Immunol (2007) 2.02
Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem (2007) 1.95
Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol (2005) 1.94
The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J Biol Chem (2003) 1.92
Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem (2005) 1.92
Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology (2009) 1.78
T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res (2012) 1.74
CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One (2006) 1.68
Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods (2008) 1.62
Monoclonal TCR-redirected tumor cell killing. Nat Med (2012) 1.57
T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility. Immunity (2009) 1.55
Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem (2009) 1.51
Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol (2010) 1.48
Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol (2012) 1.46
T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res (2005) 1.43
Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology (2008) 1.40
Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. J Bone Miner Res (2013) 1.36
A partially interpenetrated metal-organic framework for selective hysteretic sorption of carbon dioxide. Nat Mater (2012) 1.33
Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci (2006) 1.31
Structural and biophysical determinants of αβ T-cell antigen recognition. Immunology (2012) 1.30
Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J Biol Chem (2004) 1.29
Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers. Cytometry A (2008) 1.26
Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. Eur J Immunol (2007) 1.24
Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem Biophys Res Commun (2004) 1.21
Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells. PLoS Pathog (2008) 1.21
Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res (2010) 1.21
CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J Immunol (2005) 1.21
Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. Protein Eng Des Sel (2007) 1.19
Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection. PLoS Pathog (2010) 1.18
T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Mol Immunol (2008) 1.18
Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res (2008) 1.15
CD8 controls T cell cross-reactivity. J Immunol (2010) 1.15
A structural voyage toward an understanding of the MHC-I-restricted immune response: lessons learned and much to be learned. Immunol Rev (2012) 1.14
Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood (2012) 1.13
High-resolution structural insights into ligand binding and immune cell recognition by human lung surfactant protein D. J Mol Biol (2003) 1.13
Regulating the immune response to tumours. Adv Drug Deliv Rev (2006) 1.13
The 1.45 A three-dimensional structure of C-phycocyanin from the thermophilic cyanobacterium Synechococcus elongatus. J Struct Biol (2003) 1.12
Stellated polyhedral assembly of a topologically complicated Pd4L4 'Solomon cube'. Nat Chem (2009) 1.10
Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. J Clin Invest (2008) 1.09
Type I interferon (IFN alpha) acts directly on human memory CD4+ T cells altering their response to antigen. J Immunol (2009) 1.09
Complex assembly, crystallization and preliminary X-ray crystallographic studies of MHC H-2Kd complexed with an HBV-core nonapeptide. Acta Crystallogr D Biol Crystallogr (2004) 1.07
Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol (2007) 1.06
SARS coronavirus induces apoptosis in Vero E6 cells. J Med Virol (2004) 1.05
Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J Immunol Methods (2008) 1.03
Construction and crystal structure of recombinant STNV capsids. J Mol Biol (2011) 1.03
The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Mol Cancer Ther (2007) 1.01
Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope. J Immunol (2007) 1.01
Soluble T cell receptors: novel immunotherapies. Curr Opin Pharmacol (2005) 1.01
Coreceptor CD8-driven modulation of T cell antigen receptor specificity. J Theor Biol (2007) 1.00
Crystal structure of enhanced green fluorescent protein to 1.35 Å resolution reveals alternative conformations for Glu222. PLoS One (2012) 0.99
Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load. J Clin Immunol (2002) 0.99
Crystal structure of HLA-A*2402 complexed with a telomerase peptide. Eur J Immunol (2006) 0.98
The molecular basis of the coloration mechanism in lobster shell: beta-crustacyanin at 3.2-A resolution. Proc Natl Acad Sci U S A (2002) 0.98
Basis for fusion inhibition by peptides: analysis of the heptad repeat regions of the fusion proteins from Nipah and Hendra viruses, newly emergent zoonotic paramyxoviruses. Biochem Biophys Res Commun (2004) 0.96
T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting. J Biol Chem (2012) 0.96
Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. Eur J Immunol (2013) 0.96
CD8 exerts differential effects on the deployment of cytotoxic T lymphocyte effector functions. Eur J Immunol (2007) 0.96
Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. J Immunol (2011) 0.94
The molecular determinants of CD8 co-receptor function. Immunology (2012) 0.94
T-cell receptor specificity maintained by altered thermodynamics. J Biol Chem (2013) 0.94
Computational design and crystal structure of an enhanced affinity mutant human CD8 alphaalpha coreceptor. Proteins (2007) 0.93
Dyslipidemia due to retroviral protease inhibitors. Nat Med (2002) 0.93
T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions. J Biol Chem (2013) 0.93
Peptide-major histocompatibility complex dimensions control proximal kinase-phosphatase balance during T cell activation. J Biol Chem (2009) 0.93
MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs. J Immunol (2010) 0.92